Cordoba Octavi, Perez-Ceresuela Francesc, Espinosa-Bravo Martin, Cortadellas Tomas, Esgueva Antonio, Rodriguez-Revuelto Robert, Peg Vicente, Reyes Victoria, Xercavins Jordi, Rubio Isabel T
Centre de Càncer de Mama Vall d'Hebron, Service of Gynecology, Hospital Universitari Vall d'Hebron, Pg Vall d'Hebron 119-129, 08035 Barcelona, Spain; Facultat de Medicina, Universitat Autònoma de Barcelona, Unitat docent Vall d'Hebron, Vall d'Hebron 119-129, 08035 Barcelona, Spain.
Facultat de Medicina, Universitat Autònoma de Barcelona, Unitat docent Vall d'Hebron, Vall d'Hebron 119-129, 08035 Barcelona, Spain; Service of Gynecology, Hospital Universitari Hospital Universitari Vall d'Hebron, Pg Vall d'Hebron 119-129, 08035 Barcelona, Spain.
Breast. 2014 Aug;23(4):460-5. doi: 10.1016/j.breast.2014.03.007. Epub 2014 Apr 13.
Use of sentinel lymph node dissection in patients with ipsilateral breast cancer recurrence is still controversial. The objective of this study is to evaluate the feasibility of the sentinel lymph node in breast cancer recurrence (SLNBR) and whether the positivity had impact in the adjuvant treatment. Between 2008 and 2012 we performed SLNBR in patients with ipsilateral breast tumor recurrence. We included 53 patients in a prospective study. Forty-three patients (81%) had a previous axillary lymph node dissection (ALND) and ten (19%) had a previous sentinel lymph node biopsy (SLNB). Identification rate after SLNB was 50% and after ALND was 60.5% (p = 0.4). Nine patients (26%) had a positive SLNBR. Adjuvant systemic treatment was given to all the patients with a positive SLNBR and to 23 (85%) with a negative SLNBR (p = 0.29). Six patients (66%) with positive SLNBR and 4 patients (14%) with negative SLNBR underwent radiation therapy (p < 0.01). As conclusions of our study we conclude that sentinel lymph node biopsy in breast tumor recurrence is feasible and significant differences were found in the use of radiation therapy in patients with a positive SLNBR.
对同侧乳腺癌复发患者进行前哨淋巴结清扫术的应用仍存在争议。本研究的目的是评估乳腺癌复发前哨淋巴结（SLNBR）的可行性，以及前哨淋巴结阳性对辅助治疗是否有影响。在2008年至2012年期间，我们对同侧乳腺肿瘤复发患者进行了SLNBR。我们纳入了53例患者进行前瞻性研究。43例患者（81%）曾接受过腋窝淋巴结清扫术（ALND），10例（19%）曾接受过前哨淋巴结活检（SLNB）。SLNB后的识别率为50%，ALND后的识别率为60.5%（p = 0.4）。9例患者（26%）SLNBR为阳性。所有SLNBR阳性的患者以及23例（85%）SLNBR阴性的患者均接受了辅助全身治疗（p = 0.29）。6例（66%）SLNBR阳性的患者和4例（14%）SLNBR阴性的患者接受了放射治疗（p < 0.01）。作为我们研究的结论，我们得出结论，乳腺肿瘤复发时进行前哨淋巴结活检是可行的，并且在SLNBR阳性的患者中，放射治疗的使用存在显著差异。
